Comparing the current results to its competitors, Prelude Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Prelude Therapeutics Inc's competitors' average revenue growth of 6.35 %, achieved in the same quarter.
Prelude Therapeutics Inc, slower than the average decrease reported by the company's competitors of -66.91 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -66.91 %
July 9, 2024
In a groundbreaking move set to potentially revolutionize the landscape of oncology, Prelude Therapeutics has announced a collaborative clinical initiative with Merck to evaluate the efficacy of its leading-edge molecule, PRT3789, in combination with Merck s renowned anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This promising alliance focuses on tackling the formidable challenge posed by SMARCA4-mutated cancers, a subset of malignancies associated with particularly poor prognoses and limited treatment options.PRT3789 is a pioneering first-in-class small molecule engineered to be a highly selective degrader of SMARCA2, a complementary counterpart to the mutated SMARCA4. SMARCA4 mutations play a crucial role i...
February 15, 2024
In the competitive world of pharmaceutical research, companies constantly strive to innovate and develop cutting-edge therapies that can revolutionize patient care. In this article, we delve into the latest update from Prelude Therapeutics, a renowned biotechnology company specializing in oncology. We analyze their recently released full year 2023 financial results and examine their outlined key s for 2024, with a focus on their groundbreaking first-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor. Additionally, we assess the implications of these advancements for Prelude Therapeutics and the wider field of pharmaceutical sciences.Financial Results:Prelude Therapeutics full year 202...
Apellis Pharmaceuticals Inc operates under a business model that focuses on the research, development, and commercialization of novel therapies for various medical conditions, with a particular emphasis on complement immunotherapy. They aim to bring innovative drugs to market that can positively impact patients' lives worldwide.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Sources:
Prelude Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prelude Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
